From the Journals

ALS Trial Tests Celecoxib–Ciprofloxacin Combination

Dual-drug therapy showed signals of slower disease progression and reduced complications in patients with ALS.

Share

A phase 2b trial assessed the fixed-dose combination of celecoxib and ciprofloxacin (PrimeC) in 68 patients with amyotrophic lateral sclerosis (ALS). The study revealed a safety profile comparable to placebo, with potential for slower functional decline as indicated by the ALS Functional Rating Scale–Revised (ALSFRS-R) scores. After 18 months, PrimeC users experienced fewer complications and exhibited trends toward improved survival. The study showed changes in biomarkers, supporting the need for further exploration of PrimeC as a potential disease-modifying therapy.

Original Source(s)

ALS Trial Tests Celecoxib–Ciprofloxacin Combination

  • by Kathryn Wighton

  • March 17, 2026

Related Content

Aneurysmal Hemorrhage Triggers Systemic Effects

Researchers examine physiologic responses following rupture and link them to outcomes.

AF Stroke Prevention: Testing Ablation

In the randomized STABLED trial, adding catheter ablation to edoxaban did not reduce recurrent stroke or major cardiovascular outcomes.

Physician Burnout: How a Neurocritical Care/Stroke Physician Manages Work-Life Balance

May A. Kim-Tenser, MD, MHA, a neurointensivist/vascular neurologist shares her tips for combatting physician burnout.

  • by

  • March 16, 2026

  • 7 min